ClinicalTrials.gg
RecruitingNCT07409571Updated May 22, 2026

Palatal Wound Healing After Free Gingival Graft Surgery

An interventional study of kollajen membran (Cytoplast™ RTMFOAM™, Osteogenics Biomedical Inc., Texas, ABD) and triamcinolone acetonide in Gingival Recession, Localized, Postoperative Morbidity and Palatal Donor Site Wound Healing, sponsored by Kahramanmaras Sutcu Imam University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Kahramanmaras Sutcu Imam University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Gingival Recession with a site in Turkey — 13 open to participants now, 14 under way, none of them phase 3. Gingival Recession · Turkey.

Planned enrollment
6th of 56
55 · median 37
Started
2025
with 8 others
No phase
52 of 69
11 open now
Primary completion
2026-05
later than 7 of 13 live
Registered
57th of 69
by date
Lead sponsor
3 of 69
Kahramanmaras Sutcu Imam University

Among the 69 studies in Gingival Recession with a site in Turkey, this one is the 6th largest by planned enrollment of the 56 interventional ones that give a count, is one of 9 that started in 2025, is one of 52 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 57th registered.

Gingival Recession

430 studies on the registry are indexed under Gingival Recession; 105 are open to participants now.

Browse Gingival Recession studies →

Open to participants now

13 of the 69 studies in Gingival Recession with a site in Turkey are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 63 Gingival Recession studies recruiting now, 30 (48%) set no upper age limit and 30 (48%) stop at 75 or younger; 1 takes children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Gingival Recession with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled clinical trial aims to evaluate the effects of topical triamcinolone acetonide application on wound healing and patient-reported outcomes at the palatal donor site following free gingival graft (FGG) surgery. A total of 55 patients with mucogingival deficiencies requiring FGG will be randomly assigned to either a control group receiving a collagen membrane or a test group receiving topical triamcinolone acetonide at the donor site. All palatal donor areas will be protected with a periodontal dressing. Clinical assessments will be performed on postoperative days 3, 7, 14, and 30. Wound epithelialization will be evaluated using the hydrogen peroxide bubbling test, while wound healing and scar formation will be assessed using the Landry, Turnbull, and Howley index and the modified Manchester Scar Scale, respectively. Patient-centered outcomes, including postoperative pain, discomfort, analgesic consumption, and oral health-related quality of life, will be assessed using visual analog scales and the Oral Health Impact Profile-14 questionnaire. The findings of this study are expected to provide evidence regarding the potential benefits of topical corticosteroid use in reducing palatal donor site morbidity following FGG surgery.

Read the detailed description

Free gingival graft (FGG) surgery is widely used in periodontal plastic surgery to increase the width of keratinized gingiva and to treat mucogingival defects around teeth and dental implants. The palatal mucosa is considered the preferred donor site for FGG procedures due to its favorable anatomical characteristics and adequate tissue thickness. However, harvesting a free gingival graft results in a secondary-intention wound at the palatal donor site, which is commonly associated with postoperative pain, discomfort, bleeding, and delayed wound healing, adversely affecting patient compliance and quality of life.

Various biomaterials and therapeutic approaches have been proposed to reduce palatal donor site morbidity and to promote wound healing following FGG surgery, including collagen-based materials, platelet concentrates, low-level laser therapy, ozone therapy, and topical agents. Corticosteroids are potent anti-inflammatory drugs that inhibit the arachidonic acid pathway, reduce capillary permeability, suppress fibroblast proliferation, and decrease the production of inflammatory mediators, thereby contributing to reduced postoperative inflammation and pain. Triamcinolone acetonide, a corticosteroid commonly used in oral medicine, has demonstrated beneficial effects in the management of oral ulcerative and inflammatory lesions. However, to the best of our knowledge, there is no clinical study evaluating the effects of topical triamcinolone acetonide application on palatal donor site wound healing following FGG surgery.

This randomized controlled clinical trial will include 55 systemically healthy patients presenting with insufficient attached gingiva and/or gingival recession, for whom FGG surgery is indicated. Participants will be randomly allocated into two groups. In the control group, a collagen hemostatic absorbable sponge will be applied to the palatal donor site following graft harvesting. In the test group, topical triamcinolone acetonide will be applied to the palatal donor site. In both groups, the donor area will be covered with sterile aluminum foil and a periodontal dressing to standardize wound protection.

All surgical procedures will be performed by a single experienced clinician to ensure procedural consistency. Postoperative evaluations will be conducted on days 3, 7, 14, and 30. Wound epithelialization will be assessed using the hydrogen peroxide (H₂O₂) bubbling test. Wound healing quality will be evaluated using the Landry, Turnbull, and Howley healing index, and scar formation will be assessed using the modified Manchester Scar Scale. Patient-reported outcomes, including postoperative pain, discomfort, bleeding, changes in dietary habits, and analgesic consumption, will be recorded using visual analog scales. Oral health-related quality of life will be assessed using the Oral Health Impact Profile-14 (OHIP-14) questionnaire.

The results of this study are expected to clarify the potential role of topical triamcinolone acetonide in enhancing wound healing and reducing patient morbidity at the palatal donor site following free gingival graft surgery, thereby contributing to evidence-based clinical decision-making in periodontal plastic surgery.

03

Conditions studied

  • Gingival Recession, Localized
  • Postoperative Morbidity
  • Palatal Donor Site Wound Healing

Browse trials for

Keywords

  • Free Gingival Graft
  • Palatal Donor Site
  • Wound Healing
  • Triamcinolone Acetonide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older
  • Patients presenting with insufficient attached gingiva and/or gingival recession requiring free gingival graft surgery
  • Systemically healthy individuals ()
  • Full-mouth plaque score (FMPS) \< 15% and full-mouth bleeding score (FMBS) \< 15% at the time of surgery
  • Ability and willingness to provide written and comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Presence of systemic diseases that may affect wound healing (e.g., diabetes mellitus, immunological disorders)
  • Use of systemic , drugs, or anti-inflammatory medications within the last 3 months
  • Current smokers or tobacco users
  • Pregnancy or lactation
  • History of periodontal surgery at the palatal donor site
  • Presence of active infection, ulceration, or pathological lesions at the palatal donor area
  • Known allergy or to corticosteroids, collagen materials, or study-related medications
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
55 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Participants in this group will undergo free gingival graft surgery. Following graft harvesting, a kollajen membran (Cytoplast™ RTMFOAM™, Osteogenics Biomedical Inc., Texas, ABD) will be applied to the palatal donor site

    Device: kollajen membran (Cytoplast™ RTMFOAM™, Osteogenics Biomedical Inc., Texas, ABD)

  • Experimental
    Test Group

    Participants in this group will receive a free gum graft procedure. After the graft is harvested, topical triamcinolone acetonide will be applied to the palatal donor area, and a collagen membrane (Cytoplast™ RTMFOAM™, Osteogenics Biomedical Inc., Texas, USA) will be placed over it.

    Drug: triamcinolone acetonide

Interventions

  • Devicekollajen membran (Cytoplast™ RTMFOAM™, Osteogenics Biomedical Inc., Texas, ABD)

    A kollajen membran (Cytoplast™ RTMFOAM™, Osteogenics Biomedical Inc., Texas, ABD) will be applied to the palatal donor site following free gingival graft harvesting to control bleeding and support wound healing. The donor area will be covered with sterile aluminum foil and a periodontal dressing.

  • Topical triamcinolone acetonide will be applied to the palatal donor site following free gingival graft harvesting to reduce postoperative inflammation and improve wound healing. The donor area will be covered with sterile aluminum foil and a periodontal dressing.

06

What researchers measure

Primary outcomes

  1. Oral Health-Related Quality of Life

    Oral health-related quality of life was evaluated using the Oral Health Impact Profile-14 questionnaire. The scale consists of 14 items scored on a 5-point Likert scale ranging from 0 (never) to 4 (very often). Total scores range from 0 to 56, with higher scores indicating poorer oral health-related quality of life.

    Time frame: Postoperative Days 3, 7, 14, and 30

  2. Number of participants with complete wound epithelialization

    Epithelialization of the palatal donor site will be evaluated using the hydrogen peroxide (H₂O₂) bubbling test. The presence of bubbling will be recorded as absence of epithelialization, whereas the absence of bubbling will indicate complete epithelialization.

    Time frame: Postoperative Days 3, 7, 14, and 30

  3. Wound Healing at the Palatal Donor Site

    Soft tissue healing was assessed using the Landry, Turnbull, and Howley Healing Index . The index is scored on a 5-point scale ranging from 1 to 5, where higher scores indicate better wound healing.

    Time frame: Postoperative Days 3, 7, 14, and 30

  4. Scar Formation

    Scar formation at the palatal donor site, including color match, contour, and tissue deformity, will be evaluated using the Modified Manchester Scar Scale, which is scored on a scale ranging from 0 to 4, where higher scores indicate poorer scar outcomes.

    Time frame: Postoperative Days 3, 7, 14, and 30

Secondary outcomes

  1. Postoperative Pain and Discomfort

    Postoperative pain, discomfort, bleeding, and changes in dietary habits will be evaluated using a 0-10 visual analog scale (VAS) completed by the participants.

    Time frame: Postoperative Days 1, 2, 3, 4, 5, 6, 7 and 14

  2. Analgesic Consumption

    The total number of analgesic tablets consumed during the first postoperative week will be recorded.

    Time frame: Postoperative Days 1, 2, 3, 4, 5, 6, 7 and 14

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Murugan AJ, Ganesan A, Aniyan YK, Lakshmi KC, Asokan K. Comparison of topical purslane & topical 0.1% triamcinolone acetonide in the management of oral lichen planus - a double blinded clinical trial. BMC Oral Health. 2023 Sep 19;23(1):678. doi: 10.1186/s12903-023-03385-1. PubMed 37726676 ↗
  • Siponen M, Huuskonen L, Kallio-Pulkkinen S, Nieminen P, Salo T. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. Oral Dis. 2017 Jul;23(5):660-668. doi: 10.1111/odi.12653. Epub 2017 Mar 31. PubMed 28168769 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared in order to protect patient privacy and confidentiality, in accordance with ethical standards and institutional data protection policies.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for May 2026, 7 months after the start.

Of 237 non-industry interventional studies with no phase under Gingival Recession, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 7 months is below that.

Counting every sponsor, half of 239 studies reached it within 19 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 13, 2026
StartActual
Oct 16, 2025
Primary completionEst.
May 20, 2026
CompletionEst.
May 20, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409571
Responsible party
Esra Bozkurt (Assistant Professor, Kahramanmaras Sutcu Imam University) — Principal investigator
First posted
Feb 13, 2026
Start date
Oct 16, 2025
Primary completion
May 20, 2026 (estimated)
Completion
May 20, 2026 (estimated)
Last update
May 22, 2026

Study contacts

esra bozkurt
Contact
dtesrabozkurt@gmail.com
+905533618725

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion